AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
about
Patient education in the management of coronary heart diseasePatient education in the contemporary management of coronary heart diseasePrognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology studyEffects of some common food constituents on cardiovascular diseaseColesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of actionStatins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trialShould women be offered cholesterol lowering drugs to prevent cardiovascular disease? YesEmbolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical PracticeClinical research in cardiac rehabilitation and secondary prevention: looking back and moving forwardCoronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) StudyA Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic RatsAtherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsNon-ST segment elevation acute coronary syndromes: treatment guidelines for the nurse practitionerDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospitalFactors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease.Duration of balloon inflation for optimal stent deployment: five seconds is not enough.Cardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline dataIntegrating depression and chronic disease care among patients with diabetes and/or coronary heart disease: the design of the TEAMcare study.Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010.One third of hospital costs for atherothrombotic disease are attributable to readmissions: a linked data analysisCharacteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registry.Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry.Utility of electronic patient records in primary care for stroke secondary prevention trials.Hospitalization in community-dwelling persons with Alzheimer's disease: frequency and causes.Secondary prevention of heart disease--knowledge among cardiologists and omega-3 (omega-3) fatty acid prescribing behaviors in Karachi, Pakistan.Associations between statins and COPD: a systematic review.Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.Time trends in preventive drug treatment after myocardial infarction in older patientsAspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational StudySmoking intensity and lipoprotein abnormalities in active smokersCosts and benefits of free medications after myocardial infarction.Underutilization of cardiovascular medications: effect of a continuity-of-care programSmoking, clopidogrel, and mortality in patients with established cardiovascular disease.Adrenal Function in females with low plasma HDL-C due to mutations in ABCA1 and LCAT.Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease.Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity.Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database studySmoking prevalence among US veterans.
P2860
Q24234587-C4D61158-8694-4A44-BD70-8FA70EB42205Q24235868-FFC4D989-4900-44BD-9F74-102D94399F53Q24289043-13360275-2BFA-4AFC-872C-0C0C45BCB481Q24605384-315B311A-A1CB-4967-8ED5-EC67A02F3612Q24613405-FB763E52-A403-490F-98C1-6569E6D8EBB8Q24632679-551235B2-8D54-4E5A-A875-4C0F4749F6FFQ24685830-5F27B21F-5F3F-4206-945E-D9AEE7BC4634Q26752352-78FE5930-3BE2-4AE8-A544-4162358CF6BEQ26864794-5E591CE2-125B-471A-A03F-E4383F3559F4Q27026525-82FC3E84-50D2-4E10-B9FB-8A847E9B511BQ27348866-4424FE24-23EA-4071-B294-5D12382E89ABQ28200554-BE404CAB-FEEC-47C4-BE54-40AFE4726048Q28211708-7D51AB72-9B0B-47FC-866E-DDA93A42E66AQ28222549-9802F6AD-EE33-44D4-91F6-B273D8CAAAD4Q28480623-5DDDB9BB-1F30-48BB-B0EA-1A761FB2939FQ30384321-812F65D9-DDD3-4A8A-B952-8CBADF797A31Q30409866-8AEE0549-BB79-4F5B-BFDB-32EFAC21758FQ30530802-D58449EA-D96E-4E23-B02C-4E74E41E2E31Q30541872-03EE7D87-0CD3-402D-8A98-ED5A8A33E864Q30585937-E4B06E81-132F-4402-A430-7C4F2050973DQ30651756-350FB6ED-6C9F-4A9D-A59D-A6FE9DDE5729Q30841242-D17A0BEF-F58E-493C-BC9D-AC3BB01629EDQ30871991-72F42321-FD05-4973-A5C7-AD583913237AQ30953720-7B0EB1CA-66E8-45F0-8ECC-E6419424673BQ30998805-DE67773D-9C39-446B-BF74-D0EE7B805732Q33158873-E9F08047-817A-4937-829D-DBFBA571153BQ33403376-391B80EB-7E28-4FD7-9AD0-634A51058F37Q33481269-C873D008-E8E4-4CD9-A73D-CC57BD2975D0Q33559274-ADAD6E9F-7B05-4666-BA34-EF307A177070Q33571940-E74DB8B7-B5DD-4461-BF81-37EA284DD9E8Q33572424-D343C9DE-1712-476E-9AD6-6B6F5A3F43FAQ33573077-761391A6-AA92-45B9-8185-2A487AD99A53Q33585275-D46304A3-DFDA-4CCB-82DB-E0C06B984C7CQ33603741-FFD031EC-402C-4506-B517-1A9BA1F48E0DQ33621896-8995740E-AEC8-40C8-9A6A-E93E012CF2C6Q33632173-F25B15AF-66E3-4538-B18A-2C4E57ED0BB7Q33642534-E1ECA0F4-0B9F-41EB-8994-BE31722EA34BQ33672059-51081322-BA10-4C70-9C4C-0766D5FC086FQ33719272-678700D7-F0B5-4213-B213-00AD1E899E38Q33723298-C08A4560-7B42-4F94-BA59-74E45B78226D
P2860
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
description
article
@en
im Mai 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2006
@uk
name
AHA/ACC Guidelines for Seconda ...... Vascular Disease: 2006 Update
@en
AHA/ACC Guidelines for Seconda ...... Vascular Disease: 2006 Update
@nl
type
label
AHA/ACC Guidelines for Seconda ...... Vascular Disease: 2006 Update
@en
AHA/ACC Guidelines for Seconda ...... Vascular Disease: 2006 Update
@nl
prefLabel
AHA/ACC Guidelines for Seconda ...... Vascular Disease: 2006 Update
@en
AHA/ACC Guidelines for Seconda ...... Vascular Disease: 2006 Update
@nl
P2093
P50
P1433
P1476
AHA/ACC Guidelines for Seconda ...... Vascular Disease: 2006 Update
@en
P2093
Daniel Jones
Jerilyn Allen
Kathryn A. Taubert
Lawrence M. Brass
Loren Hiratzka
Lori Mosca
Marc A. Pfeffer
Richard C. Pasternak
Robert O. Bonow
Scott M. Grundy
P304
P356
10.1161/CIRCULATIONAHA.106.174516
P407
P577
2006-05-16T00:00:00Z